Bindarit

Modify Date: 2026-07-04 08:08:17

Bindarit Structure
Bindarit structure
Common Name Bindarit
CAS Number 130641-38-2 Molecular Weight 324.374
Density 1.2±0.1 g/cm3 Boiling Point 542.9±40.0 °C at 760 mmHg
Molecular Formula C19H20N2O3 Melting Point N/A
MSDS N/A Flash Point 282.1±27.3 °C

 Use of Bindarit


Bindarit(AF-2838), a CCL2, CCL7 and CCL8 inhibitor, is an anti-inflammatory agent.Target: OthersBindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. Oral administration of Bindarit at 50 mg/kg in NZB/W mice delays the onset of proteinuria, significantly protects from renal function impairment, and prolongs survival of NZB/W mice or lupus mice. Bindarit treatment completely MCP-1 up-regulation during the progression of nephritis [1]. Inhibition of MCP-1 with Bindarit also reduces tumor growth and macrophage recruitment, rendering necrotic tumor masses in human melanoma xenografts [2]. Bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content [3]. Administration of Bindarit results in impaired metastatic disease in prostate cancer PC-3M-Luc2 xenograft mice and impairment of local tumorigenesis in Balb/c mice with murine breast cancer 4T1-Luc cells. In addition, Bindarit treatment significantly decreases the infiltration of tumor-associated macrophages and myeloid-derived suppressor cells in 4T1-Luc primary tumors [4].

 Names

Name 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
Synonym More Synonyms

 Bindarit Biological Activity

Description Bindarit(AF-2838), a CCL2, CCL7 and CCL8 inhibitor, is an anti-inflammatory agent.Target: OthersBindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. Oral administration of Bindarit at 50 mg/kg in NZB/W mice delays the onset of proteinuria, significantly protects from renal function impairment, and prolongs survival of NZB/W mice or lupus mice. Bindarit treatment completely MCP-1 up-regulation during the progression of nephritis [1]. Inhibition of MCP-1 with Bindarit also reduces tumor growth and macrophage recruitment, rendering necrotic tumor masses in human melanoma xenografts [2]. Bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content [3]. Administration of Bindarit results in impaired metastatic disease in prostate cancer PC-3M-Luc2 xenograft mice and impairment of local tumorigenesis in Balb/c mice with murine breast cancer 4T1-Luc cells. In addition, Bindarit treatment significantly decreases the infiltration of tumor-associated macrophages and myeloid-derived suppressor cells in 4T1-Luc primary tumors [4].
Related Catalog
References

[1]. Zoja, C., et al., Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int, 1998. 53(3): p. 726-34.

[2]. Gazzaniga, S., et al., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol, 2007. 127(8): p. 2031-41.

[3]. Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93.

[4]. Zollo, M., et al., Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis, 2012. 29(6): p. 585-601.

 Chemical & Physical Properties

Density 1.2±0.1 g/cm3
Boiling Point 542.9±40.0 °C at 760 mmHg
Molecular Formula C19H20N2O3
Molecular Weight 324.374
Flash Point 282.1±27.3 °C
Exact Mass 324.147400
PSA 64.35000
LogP 3.44
Vapour Pressure 0.0±1.5 mmHg at 25°C
Index of Refraction 1.595
InChIKey MTHORRSSURHQPZ-UHFFFAOYSA-N
SMILES CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(=O)O

 Safety Information

Hazard Codes Xi
HS Code 2933990090

 Synthetic Route

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

~%

Bindarit Structure

Bindarit

CAS#:130641-38-2

Learn More
Literature: WO2011/15501 A1, ;

 Customs

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 BindaritBioassay

View more

Name: Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident pro...
Source: NCGC
Target: N/A
External Id: SERCaMPGLuc-p1-antagonist
Name: Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression
Source: NCGC
External Id: SNCA-p-activity-luciferase
Name: Primary qHTS for Identification of Small Molecule Activators of Huntingtin-Antisense ...
Source: NCGC
External Id: huntington-HTTAS8-p1-FF-overN
Name: Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry
Source: NCGC
Target: N/A
External Id: TRND-SARS-CoV-2-cytotox-48hr
Name: Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry
Source: NCGC
External Id: TRND-SARS-CoV-2-PP
Name: Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against th...
Source: NCGC
Target: N/A
External Id: s-my-keats_OPM1-m4-1
Total 113, Current Page 1 of 12
1
2
3
4
5

 Synonyms

2-[(1-Benzyl-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid
Bindarit (USAN/INN)
2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid
bindarit
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.